MINERALYS THERAPEUTICS, INC. Shareholders' Equity
MINERALYS THERAPEUTICS, INC. (MLYS) had Shareholders' Equity of $550.92 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent $550.92M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $638.14M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $646.69M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $576.43M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $550.92M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $638.14M 10-Q · filed 2026-08-11 |
| 2025-12-31 | $646.69M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $576.43M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $313.55M 10-Q · filed 2026-08-11 |
| 2025-03-31 | $341.56M 10-Q · filed 2026-08-11 |
| 2024-12-31 | $191.26M 10-Q · filed 2026-08-11 |
| 2024-09-30 | $236.93M 10-Q · filed 2025-11-10 |
| 2024-06-30 | $290.10M 10-Q · filed 2025-11-10 |
| 2024-03-31 | $328.05M 10-Q · filed 2025-11-10 |
| 2023-12-31 | $241.15M 10-K · filed 2026-03-12 |
| 2023-09-30 | $264.01M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $285.01M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $295.88M 10-Q · filed 2024-11-12 |
| 2022-12-31 | -$52.27M 10-K · filed 2025-02-12 |
| 2022-09-30 | -$43.41M 10-Q · filed 2023-11-07 |
| 2022-06-30 | -$36.93M 10-Q · filed 2023-11-07 |
| 2022-03-31 | -$30.48M 10-Q · filed 2023-11-07 |
| 2021-12-31 | -$22.93M 10-K · filed 2024-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |